ID   CHLA-79
AC   CVCL_6608
SY   CHLA_79
DR   Cosmic; 930044
DR   Cosmic; 1019943
DR   Cosmic; 1161983
DR   IARC_TP53; 23824
DR   Wikidata; Q54812506
RX   PubMed=9850071;
RX   PubMed=11212268;
RX   PubMed=11507071;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=23202128;
RX   PubMed=24792489;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071).
ST   Source(s): COG
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 14
ST   D19S433: 14,15
ST   D21S11: 30,30.2
ST   D2S1338: 17,23
ST   D3S1358: 17,18
ST   D5S818: 11,13
ST   D7S820: 8,9
ST   D8S1179: 12
ST   FGA: 20,21
ST   TH01: 8,9.3
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=9850071;
RA   Keshelava N., Seeger R.C., Groshen S., Reynolds C.P.;
RT   "Drug resistance patterns of human neuroblastoma cell lines derived
RT   from patients at different phases of therapy.";
RL   Cancer Res. 58:5396-5405(1998).
//
RX   PubMed=11212268;
RA   Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P.,
RA   Brodeur G.M., White P.S.;
RT   "Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36
RT   or at other tumor suppressor loci in neuroblastoma.";
RL   Cancer Res. 61:679-686(2001).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261; PMCID=PMC2672043;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493; PMCID=PMC3557959;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//